The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing
Abstract
Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, there are data to suggest that care for T1D has improved as evidenced by reduced rates of microvascular disease in the past decades109–111, whereas data on CVD suggest that substantially less progress has been made in reduction of macrovascular disease rates111–113.”
From Epidemiology of type 1 diabetes (2010) · cites this paper as [112]
In the citing paper
“the AHA categorizes type 1 children in the highest tier for cardiovascular risk and recommends both lifestyle and pharmacologic treatment for those with elevated LDL cholesterol levels (285,286).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [286]
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Prevalence and Trends in Overweight Among US Children and Adolescents, 1999-2000
Ogden, C. L. (2002) · JAMA · doi:10.1001/jama.288.14.1728 · Cited by 4,060
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S. K., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,506
Freedman, D. S., Dietz, W. H., Srinivasan, S. R., & Berenson, G. S. (1999) · Pediatrics · doi:10.1542/peds.103.6.1175 · Cited by 2,456
Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420302 · Cited by 1,957
Relation of Body Fat Distribution to Metabolic Complications of Obesity*
KISSEBAH, A. H., VYDELINGUM, N., MURRAY, R., EVANS, D. J., KALKHOFF, R. K., & ADAMS, P. W. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-2-254 · Cited by 1,909
Overweight in Children and Adolescents
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., Robinson, T. N., Scott, B. J., Jeor, S. S., & Williams, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000161369.71722.10 · Cited by 1,543
Self-citationKrotkiewski, M., Björntorp, P. A., Sjöström, L., & Smith, U. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111040 · Cited by 1,475
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
Bønaa, K. H., Njølstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., & Rasmussen, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055227 · Cited by 1,442
Research works printed but not linked: 13
- 10.1161/atvb.15.9.1512 · DOI
- 10.1161/circ.89.5.8181179 · DOI
- 10.1161/circ.103.11.1546 · DOI
- 10.1161/circ.103.22.2705 · DOI
- 10.1161/circ.104.23.2815 · DOI
- 10.1161/atvb.16.8.984 · DOI
- 10.1161/atvb.20.9.2070 · DOI
- 10.1161/circ.101.13.1533 · DOI
- 10.1161/hyp.26.6.984 · DOI
- 10.1016/S0891-5245(02)06571-9 · DOI
- Firth JC, Marais AD, Byrnes P, Fusco RA, Bonnici F. Fluvastatin in heterozygous familial hypercholesterolemia. Cardiol Young. 2000; 10 (suppl 2): 35. Abstract.
- 10.1161/circ.102.13.1477 · DOI
- 10.1161/circ.94.6.1386 · DOI
Cited by
Sorted by citations
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Metadata
- Authors
- McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., & Daniels, S. R.
- Affiliations
- Hospital for Sick Children (CA)
- ORCID
- Venue
- Circulation
- Published
- 2007-04-10
- Volume
- 115
- Issue
- 14
- Pages
- 1948-1967
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2070344375
- Cited by
- 418
- References
- 153
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 8 · 2020: 19 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 18 · 2015: 23 · 2014: 26 · 2013: 32 · 2012: 36
- FWCI
- 53.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- familial hypercholesterolemia, severe hypercholesterolemia, lipid-lowering therapy, statins, early atherosclerosis, children and adolescents, patient selection, treatment monitoring
- MeSH terms
- Contraindications, Adolescent, Adult, Age Factors, Anticholesteremic Agents, Hypolipidemic Agents, Arteriosclerosis, Child, Child, Preschool, Cholesterol, Dietary, Clinical Trials as Topic, Combined Modality Therapy, Dietary Fats, Exercise Therapy, Female, Humans, Hyperlipoproteinemia Type II, Hyperlipoproteinemias, Infant, Cholesterol, LDL, Male, Phytotherapy, Middle Aged, Obesity, Risk Factors, Ultrasonography, HIV Infections, HIV Protease Inhibitors, Age of Onset, Disease Progression, Diet, Fat-Restricted, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Metabolic Syndrome, Diabetes Complications, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
